What is Quality Biological?
Quality Biological operates as a critical partner in the life sciences supply chain, specializing in the transition of research concepts from proof-of-concept to full-scale commercialization. Based in Gaithersburg, Maryland, the company provides essential bioprocessing components, including customized cell culture media, buffers, and molecular biology reagents. Their service model is designed to support clients across the entire product development lifecycle, from initial bench-scale research to large-scale Good Manufacturing Practice (GMP) production.
By offering personalized formulation services and technical research support, Quality Biological serves as a vital bridge for biotech firms navigating the complexities of pre-clinical studies and new product development. Their expertise in high-volume, high-precision manufacturing makes them a cornerstone for organizations requiring reliable, scalable biological solutions.
How much funding has Quality Biological raised?
Quality Biological has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Quality Biological
PPP
Public-Private Partnership
What's next for Quality Biological?
With the recent influx of capital, Quality Biological is poised to enhance its GMP manufacturing footprint and broaden its service offerings. The strategic focus will likely center on optimizing production efficiencies to accommodate the increasing demand for specialized reagents in the biopharmaceutical industry. As the company moves forward, the emphasis will remain on scaling its infrastructure to support the next generation of therapeutic breakthroughs.
Furthermore, the firm is expected to leverage this financial backing to deepen its research support capabilities, ensuring that its partners can achieve their development milestones with greater speed and precision. By reinforcing its position as a reliable, high-capacity supplier, Quality Biological is set to play an increasingly pivotal role in the commercialization of advanced biological products.
